These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17690930)

  • 1. Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club.
    Body JJ; Bergmann P; Boonen S; Boutsen Y; Devogelaer JP; Goemaere S; Reginster JY; Rozenberg S; Kaufman JM
    Osteoporos Int; 2007 Nov; 18(11):1439-50. PubMed ID: 17690930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of side-effects of systemic treatment: bone loss.
    Body JJ
    Ann Oncol; 2010 Oct; 21 Suppl 7():vii180-5. PubMed ID: 20943612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
    J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
    Brufsky AM
    Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Tang SC
    Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone health during endocrine therapy for cancer.
    Rachner TD; Coleman R; Hadji P; Hofbauer LC
    Lancet Diabetes Endocrinol; 2018 Nov; 6(11):901-910. PubMed ID: 29572126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
    Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
    Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer treatment-induced bone loss in breast and prostate cancer.
    Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
    J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
    Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
    Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.